Full Text CA-93-02 THE REGULATION, FUNCTION AND SPECIFICITY OF PROTEINS INDUCED IN MAMMALIAN CELLS EXPOSED TO IONIZING RADIATION NIH GUIDE, Volume 21, Number 38, October 23, 1992 RFA: CA-93-02 P.T. 34 Keywords: Proteins and Macromolecules Gene Regulation Gene Products National Cancer Institute Letter of Intent Receipt Date: December 10, 1992 Application Receipt Date: February 10, 1993 PURPOSE The Division of Cancer Etiology of the National Cancer Institute (NCI) invites grant applications from interested investigators through an announcement of Request for Applications (RFA) for studies of the function and regulation of proteins differentially expressed in mammalian cells exposed to ionizing radiation. The RFA will emphasize direct analysis of the genes and gene products associated with ionizing irradiation of mammalian cells. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, The Function, Regulation and Specificity of Proteins Induced in Cells Exposed to Ionizing Radiation, is related to the priority area of biomedical research. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001- 00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit institutions, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the Federal government. Applications from minority individuals and women are encouraged. MECHANISM OF SUPPORT This RFA is a one-time solicitation and will be supported through the National Institutes of Health (NIH) traditional research project grant (R01). The applicant will have the sole responsibility for planning, directing, and executing the proposed research. Awards will be administered under Public Health Service grants policy as stated in the PHS Grants Policy Statement, DHHS Publication No. (OASH) 90-50,000 revised October 1, 1990. The total project period for each application submitted in response to the present RFA should not exceed four years. Competitive continuation applications will compete with all other unsolicited applications and be reviewed by a standing Division of Research Grants study section. FUNDS AVAILABLE The intent of this research initiative is to fund approximately six individual research grants, with total program costs not to exceed $1,000,000 for the first year. This funding level will be dependent on receipt of a sufficient number of grant proposals of high scientific merit. Support for this RFA is provided for in the financial plans of the NCI. However, award of grants responding to this RFA will be contingent on the availability of funds at the time the awards are made. RESEARCH OBJECTIVES Background Recent evidence suggests that mammalian cells possess a specific and limited set of radiation modulated proteins (RMPs) that are differentially expressed in response to ionizing irradiation. The overall process of RMP structural gene expression appears to be tightly regulated, mainly at the level of gene transcription, and demonstrates a radiation dose-response (e.g., from less than 20 cGy to over 300 cGy). The molecular lesion(s) that initiates this process is not known. Many RMPs have been detected only as peptides or as new gene transcripts (herein called uncharacterized RMPs) and appear to be specifically induced by ionizing irradiation and not by other agents known to induce stress-related proteins (e.g., heat, hypoxia, ultraviolet light, chemical carcinogens). Few, if any, of the cDNAs corresponding to the uncharacterized RMPs have been cloned. Accordingly, there is little detailed molecular and biochemical information on the functions carried out by the uncharacterized RMPs or on the genetic and regulatory mechanisms that control their expression. However, there is circumstantial evidence suggesting that increased expression of several of the uncharacterized RMPs is correlated with cellular recognition of radiogenic lesions to DNA, the repair of ionizing-radiation-induced DNA damage, and possibly with the radiation-induced arrest of the cell cycle suggesting intimate involvement in classical radiologic endpoints of DNA-repair and inhibition of DNA-synthesis, gene transcription, and cell division. Objectives Because of advances in the technology for detection of minute quantities of gene products, both transcripts and proteins, it should be feasible to directly study the genes expressed in mammalian cells exposed to ionizing radiation. Likewise, it should be possible to construct cDNA libraries from irradiated human or rodent cells that correspond to the structural genes of the uncharacterized RMPs. Such libraries will be essential for the isolation and subsequent molecular and biochemical analyses of the uncharacterized RMP structural genes and proteins. This RFA will permit a wide range of research activities, including, but not limited to, the following objectives: o Studies to determine the biochemical and molecular functions carried out by the uncharacterized RMPs, to relate them to poorly understood radiologic endpoints in mammalian cells such as radiation-induced arrest of the cell cycle, repair of radiation damaged DNA, radiation-induced mutagenesis, transformation, and cell survival; o Research to identify the radiogenic lesions that trigger the differential expression of the uncharacterized RMPs; o Analysis of the genetic organization of the uncharacterized RMP structural genes and the mechanisms of regulation that govern their expression; o Determination of the effects of radiation quality on differential expression of the uncharacterized RMPs, specifically, the efficacy of high-LET radiation should be compared with low LET radiation for inducing the uncharacterized RMPs. STUDY POPULATIONS Special instructions to applicants regarding implementation of NIH policies concerning inclusion of females and minorities in clinical research study populations are not applicable to this RFA. LETTER OF INTENT Prospective applicants are requested to submit, by December 10, 1992, a letter of intent to respond to the RFA that includes a descriptive title of the proposed research, collaborations and/or collaborative agreements, the name and address of the Principal Investigator, the names of other key personnel, the participating institutions, and the number and title of the RFA in response to which an application may be submitted. The letter of intent helps NCI staff to estimate the review workload and to avoid possible conflict of interest in the review. The letter of intent does not bind the respondent to respond formally to the RFA, nor is it required in order to respond. The letter of intent does not enter into the review of subsequent applications. The letter of intent is to be sent to: Richard A. Pelroy, Ph.D. Radiation Effects Branch National Cancer Institute Executive Plaza North, Suite 530 Bethesda, MD 20892 Telephone: (301) 496-9326 FAX: (301) 496-1224 APPLICATION PROCEDURES Applications are to be submitted on PHS 398 (rev. 9/91) available at most institutional offices of sponsored research, and may be obtained from the Office of Grants Inquires, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 496-7447. The format and instructions applicable to regular research grant applications must be followed in preparing a grant in response to the RFA. The RFA label available in the application form PHS 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of a grant application, and possibly preventing it from reaching the review committee in time for review. In addition, the number and title of the RFA should be typed on line 2a of the face page of the application and YES must be checked. A signed, typewritten original grant application, including the checklist, and three signed, exact photocopies, must be mailed, in one package, to the Division of Research Grants at the address below. The photocopies must be clear and single-sided. Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission, two additional copies of the application must also be sent to: Referral Officer Division of Extramural Activities National Cancer Institute Westwood Building, Room 848 5333 Westbard Avenue Bethesda, MD 20892 Applications must be received by February 10, 1993. If an application is received after that date, it will be administratively withdrawn from consideration. If the application submitted in response to this RFA is substantially similar to a grant application already submitted to the NIH for review, but has not yet been reviewed, the applicant will be asked to withdraw either the pending application or the new one. Simultaneous submission of identical applications will not be allowed, nor will essentially identical applications be reviewed by different review committees. Therefore, an application cannot be submitted in response to this RFA that is essentially identical to one that has already been reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. Animal and human subject approval clearances, when applicable, should be submitted with the application to expedite the review process. REVIEW CONSIDERATIONS Review Procedures Upon receipt, applications will be reviewed by the Division of Research Grants for completeness. Incomplete applications will be returned to the applicant without further consideration. Review of the responsiveness of applications is an NCI program staff function. Applications will be judged to determine how well they meet the goals and objectives of the program as described in the RFA. Applications that are judged non-responsive will be administratively withdrawn, and the proposed Principal Investigator and institutional business official will be notified. If an application is judged non-responsive to this RFA, it may be submitted as an investigator initiated regular research grant (R01) at the next receipt date. If the number of applications is large compared to the number of awards to be made, the NCI may conduct a preliminary scientific peer review to eliminate those that are clearly not competitive for award. The NCI will withdraw from further competition those applications judged to be noncompetitive and notify the Principal Investigator and institutional business official. Those applications judged to be both competitive and responsive will be further evaluated, using the review criteria shown below, for scientific and technical merit by an appropriate peer review group convened by the Division of Extramural Activities, NCI. The second level of review by the National Cancer Advisory Board considers the special needs of the Institute and the priorities of the National Cancer Program. Review Criteria Applications should be responsive to the stated purpose and objective of the RFA. Those factors considered to be important for review will include: o The scientific merit and innovation of proposed research o A demonstrated knowledge of the applicable science and competence with relevant methodology o Adequacy of facilities and special resources relevant to the RFA o Cost effectiveness of the proposal o Quality of scientific collaboration o Technical merit of proposed methods AWARD CRITERIA The anticipated date of award is September 15, 1993. Responsiveness to the objectives of the RFA, programmatic balance and scientific merit will be major criteria for making award decisions. INQUIRIES Written and telephone inquires concerning the objectives and scope of this RFA are encouraged and may be directed to Dr. Richard A. Pelroy at the address listed under LETTER OF INTENT. AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.393, Cancer Cause and Prevention Research. Awards are made under authorization of Public Health Service Act, Section 301(c) and Section 402 (Public Law 78-410, as amended; 42 USC 241; 42 USC 282) and administered under PHS grants policies and Federal regulations 42 CFR Part 52 and 45 CFR Part 74. This program in not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |